Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers-21247/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers-21247/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers-21247/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers-21247/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68011927877d7-trace').style.display = (document.getElementById('cakeErr68011927877d7-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr68011927877d7-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68011927877d7-code').style.display = (document.getElementById('cakeErr68011927877d7-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr68011927877d7-context').style.display = (document.getElementById('cakeErr68011927877d7-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr68011927877d7-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr68011927877d7-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 21102,
		&#039;title&#039; =&gt; &#039;Ranbaxy case may take a toll on other Indian drug makers&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last week, Ranbaxy had agreed to pay a fine of $500 million to settle litigation related to selling adulterated drugs in the US market. The company was charged with an intention to defraud, as well as failing to report the fact that its drugs did not meet required specifications.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sujay Shetty, executive director at PricewaterhouseCoopers, said, &amp;quot;US FDA, which is under pressure over quality concerns, will carry out additional scrutiny over ANDAs filed by Indian generic makers, and this would definitely slow the approval process....The shortage of staff at US FDA is already causing a delay in ANDA approvals.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, Indian drug makers accounted for 178 of the 476 ANDA approvals by the US FDA. With 31 ANDA approvals, Aurobindo Pharma received the third-highest generic approvals, after Mylan Pharma and Apotex.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Tapan Ray, director general, Organisation of Pharmaceutical Producers of India, a representative entity of multinational pharmaceutical companies in India, said after recent incidents, including the Ranbaxy case, the image of India as a low-cost generic drugs manufacturer could be adversely impacted. &amp;quot;In the backdrop of such high-decibel quality concerns raised by US FDA, the level of apprehension regarding the effectiveness of generic drugs made in India may increase, unless some tangible remedial measures are taken forthwith,&amp;quot; he said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In February, Jubilant Life Sciences had received a US FDA letter that cited major violations of manufacturing standards at its facility in Canada. The US FDA might delay drug approvals until Jubilant HollisterStier General Partnership took necessary corrective steps, Jubilant had said in a statement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
D G Shah, secretary general, Indian Pharmaceutical Alliance, believes competitors in the US generics market would use the recent episodes as tools to reduce demand for Indian generic versions in that market. &amp;quot;There would be a collateral damage. Other large generic makers could create propaganda against Indian copycat drugs, through their connections with practitioners and other related parties,&amp;quot; Shah said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Not just Indian pharmaceutical companies, many others, too, had been issued cautionary letters by US FDA, either for violation of norms or for selling substandard drugs, Shah said. In March, Johnson &amp;amp; Johnson had recalled about two million glucose meters, following the death of a patient in Europe after an inaccurate blood-sugar reading.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In 2007, US-based Merck &amp;amp; Co had agreed to pay $4.85 billion to settle most claims its painkiller Vioxx had led to thousands of users reporting heart attacks and strokes. This was one of the costliest settlements in the pharmaceuticals sector.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Reghu Balakrishnan in Mumbai&lt;/em&gt;
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;Rediff.com, 24 May, 2013, http://www.rediff.com/business/report/ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers/20130524.htm&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers-21247&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 21247,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 21102,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Ranbaxy case may take a toll on other Indian drug makers&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,generic drugs&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Business Standard



The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last week, Ranbaxy had agreed to pay a fine of $500 million to settle litigation related to selling adulterated drugs in the US market. The company was charged with an intention to defraud, as well as failing to report the fact that its drugs did not meet required specifications.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sujay Shetty, executive director at PricewaterhouseCoopers, said, &amp;quot;US FDA, which is under pressure over quality concerns, will carry out additional scrutiny over ANDAs filed by Indian generic makers, and this would definitely slow the approval process....The shortage of staff at US FDA is already causing a delay in ANDA approvals.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, Indian drug makers accounted for 178 of the 476 ANDA approvals by the US FDA. With 31 ANDA approvals, Aurobindo Pharma received the third-highest generic approvals, after Mylan Pharma and Apotex.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Tapan Ray, director general, Organisation of Pharmaceutical Producers of India, a representative entity of multinational pharmaceutical companies in India, said after recent incidents, including the Ranbaxy case, the image of India as a low-cost generic drugs manufacturer could be adversely impacted. &amp;quot;In the backdrop of such high-decibel quality concerns raised by US FDA, the level of apprehension regarding the effectiveness of generic drugs made in India may increase, unless some tangible remedial measures are taken forthwith,&amp;quot; he said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In February, Jubilant Life Sciences had received a US FDA letter that cited major violations of manufacturing standards at its facility in Canada. The US FDA might delay drug approvals until Jubilant HollisterStier General Partnership took necessary corrective steps, Jubilant had said in a statement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;D G Shah, secretary general, Indian Pharmaceutical Alliance, believes competitors in the US generics market would use the recent episodes as tools to reduce demand for Indian generic versions in that market. &amp;quot;There would be a collateral damage. Other large generic makers could create propaganda against Indian copycat drugs, through their connections with practitioners and other related parties,&amp;quot; Shah said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Not just Indian pharmaceutical companies, many others, too, had been issued cautionary letters by US FDA, either for violation of norms or for selling substandard drugs, Shah said. In March, Johnson &amp;amp; Johnson had recalled about two million glucose meters, following the death of a patient in Europe after an inaccurate blood-sugar reading.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In 2007, US-based Merck &amp;amp; Co had agreed to pay $4.85 billion to settle most claims its painkiller Vioxx had led to thousands of users reporting heart attacks and strokes. This was one of the costliest settlements in the pharmaceuticals sector.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Reghu Balakrishnan in Mumbai&lt;/em&gt;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 21102,
	&#039;title&#039; =&gt; &#039;Ranbaxy case may take a toll on other Indian drug makers&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last week, Ranbaxy had agreed to pay a fine of $500 million to settle litigation related to selling adulterated drugs in the US market. The company was charged with an intention to defraud, as well as failing to report the fact that its drugs did not meet required specifications.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sujay Shetty, executive director at PricewaterhouseCoopers, said, &amp;quot;US FDA, which is under pressure over quality concerns, will carry out additional scrutiny over ANDAs filed by Indian generic makers, and this would definitely slow the approval process....The shortage of staff at US FDA is already causing a delay in ANDA approvals.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, Indian drug makers accounted for 178 of the 476 ANDA approvals by the US FDA. With 31 ANDA approvals, Aurobindo Pharma received the third-highest generic approvals, after Mylan Pharma and Apotex.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Tapan Ray, director general, Organisation of Pharmaceutical Producers of India, a representative entity of multinational pharmaceutical companies in India, said after recent incidents, including the Ranbaxy case, the image of India as a low-cost generic drugs manufacturer could be adversely impacted. &amp;quot;In the backdrop of such high-decibel quality concerns raised by US FDA, the level of apprehension regarding the effectiveness of generic drugs made in India may increase, unless some tangible remedial measures are taken forthwith,&amp;quot; he said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In February, Jubilant Life Sciences had received a US FDA letter that cited major violations of manufacturing standards at its facility in Canada. The US FDA might delay drug approvals until Jubilant HollisterStier General Partnership took necessary corrective steps, Jubilant had said in a statement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
D G Shah, secretary general, Indian Pharmaceutical Alliance, believes competitors in the US generics market would use the recent episodes as tools to reduce demand for Indian generic versions in that market. &amp;quot;There would be a collateral damage. Other large generic makers could create propaganda against Indian copycat drugs, through their connections with practitioners and other related parties,&amp;quot; Shah said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Not just Indian pharmaceutical companies, many others, too, had been issued cautionary letters by US FDA, either for violation of norms or for selling substandard drugs, Shah said. In March, Johnson &amp;amp; Johnson had recalled about two million glucose meters, following the death of a patient in Europe after an inaccurate blood-sugar reading.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In 2007, US-based Merck &amp;amp; Co had agreed to pay $4.85 billion to settle most claims its painkiller Vioxx had led to thousands of users reporting heart attacks and strokes. This was one of the costliest settlements in the pharmaceuticals sector.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Reghu Balakrishnan in Mumbai&lt;/em&gt;
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;Rediff.com, 24 May, 2013, http://www.rediff.com/business/report/ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers/20130524.htm&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers-21247&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 21247,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 21102
$metaTitle = &#039;LATEST NEWS UPDATES | Ranbaxy case may take a toll on other Indian drug makers&#039;
$metaKeywords = &#039;medicines,generic drugs&#039;
$metaDesc = &#039;
-The Business Standard



The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last week, Ranbaxy had agreed to pay a fine of $500 million to settle litigation related to selling adulterated drugs in the US market. The company was charged with an intention to defraud, as well as failing to report the fact that its drugs did not meet required specifications.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sujay Shetty, executive director at PricewaterhouseCoopers, said, &amp;quot;US FDA, which is under pressure over quality concerns, will carry out additional scrutiny over ANDAs filed by Indian generic makers, and this would definitely slow the approval process....The shortage of staff at US FDA is already causing a delay in ANDA approvals.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, Indian drug makers accounted for 178 of the 476 ANDA approvals by the US FDA. With 31 ANDA approvals, Aurobindo Pharma received the third-highest generic approvals, after Mylan Pharma and Apotex.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Tapan Ray, director general, Organisation of Pharmaceutical Producers of India, a representative entity of multinational pharmaceutical companies in India, said after recent incidents, including the Ranbaxy case, the image of India as a low-cost generic drugs manufacturer could be adversely impacted. &amp;quot;In the backdrop of such high-decibel quality concerns raised by US FDA, the level of apprehension regarding the effectiveness of generic drugs made in India may increase, unless some tangible remedial measures are taken forthwith,&amp;quot; he said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In February, Jubilant Life Sciences had received a US FDA letter that cited major violations of manufacturing standards at its facility in Canada. The US FDA might delay drug approvals until Jubilant HollisterStier General Partnership took necessary corrective steps, Jubilant had said in a statement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;D G Shah, secretary general, Indian Pharmaceutical Alliance, believes competitors in the US generics market would use the recent episodes as tools to reduce demand for Indian generic versions in that market. &amp;quot;There would be a collateral damage. Other large generic makers could create propaganda against Indian copycat drugs, through their connections with practitioners and other related parties,&amp;quot; Shah said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Not just Indian pharmaceutical companies, many others, too, had been issued cautionary letters by US FDA, either for violation of norms or for selling substandard drugs, Shah said. In March, Johnson &amp;amp; Johnson had recalled about two million glucose meters, following the death of a patient in Europe after an inaccurate blood-sugar reading.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In 2007, US-based Merck &amp;amp; Co had agreed to pay $4.85 billion to settle most claims its painkiller Vioxx had led to thousands of users reporting heart attacks and strokes. This was one of the costliest settlements in the pharmaceuticals sector.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Reghu Balakrishnan in Mumbai&lt;/em&gt;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers-21247.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Ranbaxy case may take a toll on other Indian drug makers | Im4change.org</title>
    <meta name="description" content="
-The Business Standard



The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Ranbaxy case may take a toll on other Indian drug makers</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Business Standard</div><p align="justify"><br />The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals.</p><p align="justify">Last week, Ranbaxy had agreed to pay a fine of $500 million to settle litigation related to selling adulterated drugs in the US market. The company was charged with an intention to defraud, as well as failing to report the fact that its drugs did not meet required specifications.</p><p align="justify">Sujay Shetty, executive director at PricewaterhouseCoopers, said, &quot;US FDA, which is under pressure over quality concerns, will carry out additional scrutiny over ANDAs filed by Indian generic makers, and this would definitely slow the approval process....The shortage of staff at US FDA is already causing a delay in ANDA approvals.&quot;</p><p align="justify">Last year, Indian drug makers accounted for 178 of the 476 ANDA approvals by the US FDA. With 31 ANDA approvals, Aurobindo Pharma received the third-highest generic approvals, after Mylan Pharma and Apotex.</p><p align="justify">Tapan Ray, director general, Organisation of Pharmaceutical Producers of India, a representative entity of multinational pharmaceutical companies in India, said after recent incidents, including the Ranbaxy case, the image of India as a low-cost generic drugs manufacturer could be adversely impacted. &quot;In the backdrop of such high-decibel quality concerns raised by US FDA, the level of apprehension regarding the effectiveness of generic drugs made in India may increase, unless some tangible remedial measures are taken forthwith,&quot; he said.</p><p align="justify">In February, Jubilant Life Sciences had received a US FDA letter that cited major violations of manufacturing standards at its facility in Canada. The US FDA might delay drug approvals until Jubilant HollisterStier General Partnership took necessary corrective steps, Jubilant had said in a statement.</p><p align="justify">D G Shah, secretary general, Indian Pharmaceutical Alliance, believes competitors in the US generics market would use the recent episodes as tools to reduce demand for Indian generic versions in that market. &quot;There would be a collateral damage. Other large generic makers could create propaganda against Indian copycat drugs, through their connections with practitioners and other related parties,&quot; Shah said.</p><p align="justify">Not just Indian pharmaceutical companies, many others, too, had been issued cautionary letters by US FDA, either for violation of norms or for selling substandard drugs, Shah said. In March, Johnson &amp; Johnson had recalled about two million glucose meters, following the death of a patient in Europe after an inaccurate blood-sugar reading.</p><p align="justify">In 2007, US-based Merck &amp; Co had agreed to pay $4.85 billion to settle most claims its painkiller Vioxx had led to thousands of users reporting heart attacks and strokes. This was one of the costliest settlements in the pharmaceuticals sector.</p><p align="justify"><em>Reghu Balakrishnan in Mumbai</em></p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68011927877d7-trace').style.display = (document.getElementById('cakeErr68011927877d7-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr68011927877d7-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68011927877d7-code').style.display = (document.getElementById('cakeErr68011927877d7-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr68011927877d7-context').style.display = (document.getElementById('cakeErr68011927877d7-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr68011927877d7-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr68011927877d7-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 21102,
		&#039;title&#039; =&gt; &#039;Ranbaxy case may take a toll on other Indian drug makers&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last week, Ranbaxy had agreed to pay a fine of $500 million to settle litigation related to selling adulterated drugs in the US market. The company was charged with an intention to defraud, as well as failing to report the fact that its drugs did not meet required specifications.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sujay Shetty, executive director at PricewaterhouseCoopers, said, &amp;quot;US FDA, which is under pressure over quality concerns, will carry out additional scrutiny over ANDAs filed by Indian generic makers, and this would definitely slow the approval process....The shortage of staff at US FDA is already causing a delay in ANDA approvals.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, Indian drug makers accounted for 178 of the 476 ANDA approvals by the US FDA. With 31 ANDA approvals, Aurobindo Pharma received the third-highest generic approvals, after Mylan Pharma and Apotex.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Tapan Ray, director general, Organisation of Pharmaceutical Producers of India, a representative entity of multinational pharmaceutical companies in India, said after recent incidents, including the Ranbaxy case, the image of India as a low-cost generic drugs manufacturer could be adversely impacted. &amp;quot;In the backdrop of such high-decibel quality concerns raised by US FDA, the level of apprehension regarding the effectiveness of generic drugs made in India may increase, unless some tangible remedial measures are taken forthwith,&amp;quot; he said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In February, Jubilant Life Sciences had received a US FDA letter that cited major violations of manufacturing standards at its facility in Canada. The US FDA might delay drug approvals until Jubilant HollisterStier General Partnership took necessary corrective steps, Jubilant had said in a statement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
D G Shah, secretary general, Indian Pharmaceutical Alliance, believes competitors in the US generics market would use the recent episodes as tools to reduce demand for Indian generic versions in that market. &amp;quot;There would be a collateral damage. Other large generic makers could create propaganda against Indian copycat drugs, through their connections with practitioners and other related parties,&amp;quot; Shah said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Not just Indian pharmaceutical companies, many others, too, had been issued cautionary letters by US FDA, either for violation of norms or for selling substandard drugs, Shah said. In March, Johnson &amp;amp; Johnson had recalled about two million glucose meters, following the death of a patient in Europe after an inaccurate blood-sugar reading.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In 2007, US-based Merck &amp;amp; Co had agreed to pay $4.85 billion to settle most claims its painkiller Vioxx had led to thousands of users reporting heart attacks and strokes. This was one of the costliest settlements in the pharmaceuticals sector.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Reghu Balakrishnan in Mumbai&lt;/em&gt;
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;Rediff.com, 24 May, 2013, http://www.rediff.com/business/report/ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers/20130524.htm&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers-21247&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 21247,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 21102,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Ranbaxy case may take a toll on other Indian drug makers&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,generic drugs&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Business Standard



The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last week, Ranbaxy had agreed to pay a fine of $500 million to settle litigation related to selling adulterated drugs in the US market. The company was charged with an intention to defraud, as well as failing to report the fact that its drugs did not meet required specifications.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sujay Shetty, executive director at PricewaterhouseCoopers, said, &amp;quot;US FDA, which is under pressure over quality concerns, will carry out additional scrutiny over ANDAs filed by Indian generic makers, and this would definitely slow the approval process....The shortage of staff at US FDA is already causing a delay in ANDA approvals.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, Indian drug makers accounted for 178 of the 476 ANDA approvals by the US FDA. With 31 ANDA approvals, Aurobindo Pharma received the third-highest generic approvals, after Mylan Pharma and Apotex.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Tapan Ray, director general, Organisation of Pharmaceutical Producers of India, a representative entity of multinational pharmaceutical companies in India, said after recent incidents, including the Ranbaxy case, the image of India as a low-cost generic drugs manufacturer could be adversely impacted. &amp;quot;In the backdrop of such high-decibel quality concerns raised by US FDA, the level of apprehension regarding the effectiveness of generic drugs made in India may increase, unless some tangible remedial measures are taken forthwith,&amp;quot; he said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In February, Jubilant Life Sciences had received a US FDA letter that cited major violations of manufacturing standards at its facility in Canada. The US FDA might delay drug approvals until Jubilant HollisterStier General Partnership took necessary corrective steps, Jubilant had said in a statement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;D G Shah, secretary general, Indian Pharmaceutical Alliance, believes competitors in the US generics market would use the recent episodes as tools to reduce demand for Indian generic versions in that market. &amp;quot;There would be a collateral damage. Other large generic makers could create propaganda against Indian copycat drugs, through their connections with practitioners and other related parties,&amp;quot; Shah said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Not just Indian pharmaceutical companies, many others, too, had been issued cautionary letters by US FDA, either for violation of norms or for selling substandard drugs, Shah said. In March, Johnson &amp;amp; Johnson had recalled about two million glucose meters, following the death of a patient in Europe after an inaccurate blood-sugar reading.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In 2007, US-based Merck &amp;amp; Co had agreed to pay $4.85 billion to settle most claims its painkiller Vioxx had led to thousands of users reporting heart attacks and strokes. This was one of the costliest settlements in the pharmaceuticals sector.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Reghu Balakrishnan in Mumbai&lt;/em&gt;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 21102,
	&#039;title&#039; =&gt; &#039;Ranbaxy case may take a toll on other Indian drug makers&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last week, Ranbaxy had agreed to pay a fine of $500 million to settle litigation related to selling adulterated drugs in the US market. The company was charged with an intention to defraud, as well as failing to report the fact that its drugs did not meet required specifications.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sujay Shetty, executive director at PricewaterhouseCoopers, said, &amp;quot;US FDA, which is under pressure over quality concerns, will carry out additional scrutiny over ANDAs filed by Indian generic makers, and this would definitely slow the approval process....The shortage of staff at US FDA is already causing a delay in ANDA approvals.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, Indian drug makers accounted for 178 of the 476 ANDA approvals by the US FDA. With 31 ANDA approvals, Aurobindo Pharma received the third-highest generic approvals, after Mylan Pharma and Apotex.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Tapan Ray, director general, Organisation of Pharmaceutical Producers of India, a representative entity of multinational pharmaceutical companies in India, said after recent incidents, including the Ranbaxy case, the image of India as a low-cost generic drugs manufacturer could be adversely impacted. &amp;quot;In the backdrop of such high-decibel quality concerns raised by US FDA, the level of apprehension regarding the effectiveness of generic drugs made in India may increase, unless some tangible remedial measures are taken forthwith,&amp;quot; he said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In February, Jubilant Life Sciences had received a US FDA letter that cited major violations of manufacturing standards at its facility in Canada. The US FDA might delay drug approvals until Jubilant HollisterStier General Partnership took necessary corrective steps, Jubilant had said in a statement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
D G Shah, secretary general, Indian Pharmaceutical Alliance, believes competitors in the US generics market would use the recent episodes as tools to reduce demand for Indian generic versions in that market. &amp;quot;There would be a collateral damage. Other large generic makers could create propaganda against Indian copycat drugs, through their connections with practitioners and other related parties,&amp;quot; Shah said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Not just Indian pharmaceutical companies, many others, too, had been issued cautionary letters by US FDA, either for violation of norms or for selling substandard drugs, Shah said. In March, Johnson &amp;amp; Johnson had recalled about two million glucose meters, following the death of a patient in Europe after an inaccurate blood-sugar reading.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In 2007, US-based Merck &amp;amp; Co had agreed to pay $4.85 billion to settle most claims its painkiller Vioxx had led to thousands of users reporting heart attacks and strokes. This was one of the costliest settlements in the pharmaceuticals sector.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Reghu Balakrishnan in Mumbai&lt;/em&gt;
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;Rediff.com, 24 May, 2013, http://www.rediff.com/business/report/ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers/20130524.htm&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers-21247&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 21247,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 21102
$metaTitle = &#039;LATEST NEWS UPDATES | Ranbaxy case may take a toll on other Indian drug makers&#039;
$metaKeywords = &#039;medicines,generic drugs&#039;
$metaDesc = &#039;
-The Business Standard



The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last week, Ranbaxy had agreed to pay a fine of $500 million to settle litigation related to selling adulterated drugs in the US market. The company was charged with an intention to defraud, as well as failing to report the fact that its drugs did not meet required specifications.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sujay Shetty, executive director at PricewaterhouseCoopers, said, &amp;quot;US FDA, which is under pressure over quality concerns, will carry out additional scrutiny over ANDAs filed by Indian generic makers, and this would definitely slow the approval process....The shortage of staff at US FDA is already causing a delay in ANDA approvals.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, Indian drug makers accounted for 178 of the 476 ANDA approvals by the US FDA. With 31 ANDA approvals, Aurobindo Pharma received the third-highest generic approvals, after Mylan Pharma and Apotex.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Tapan Ray, director general, Organisation of Pharmaceutical Producers of India, a representative entity of multinational pharmaceutical companies in India, said after recent incidents, including the Ranbaxy case, the image of India as a low-cost generic drugs manufacturer could be adversely impacted. &amp;quot;In the backdrop of such high-decibel quality concerns raised by US FDA, the level of apprehension regarding the effectiveness of generic drugs made in India may increase, unless some tangible remedial measures are taken forthwith,&amp;quot; he said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In February, Jubilant Life Sciences had received a US FDA letter that cited major violations of manufacturing standards at its facility in Canada. The US FDA might delay drug approvals until Jubilant HollisterStier General Partnership took necessary corrective steps, Jubilant had said in a statement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;D G Shah, secretary general, Indian Pharmaceutical Alliance, believes competitors in the US generics market would use the recent episodes as tools to reduce demand for Indian generic versions in that market. &amp;quot;There would be a collateral damage. Other large generic makers could create propaganda against Indian copycat drugs, through their connections with practitioners and other related parties,&amp;quot; Shah said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Not just Indian pharmaceutical companies, many others, too, had been issued cautionary letters by US FDA, either for violation of norms or for selling substandard drugs, Shah said. In March, Johnson &amp;amp; Johnson had recalled about two million glucose meters, following the death of a patient in Europe after an inaccurate blood-sugar reading.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In 2007, US-based Merck &amp;amp; Co had agreed to pay $4.85 billion to settle most claims its painkiller Vioxx had led to thousands of users reporting heart attacks and strokes. This was one of the costliest settlements in the pharmaceuticals sector.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Reghu Balakrishnan in Mumbai&lt;/em&gt;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers-21247.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Ranbaxy case may take a toll on other Indian drug makers | Im4change.org</title>
    <meta name="description" content="
-The Business Standard



The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Ranbaxy case may take a toll on other Indian drug makers</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Business Standard</div><p align="justify"><br />The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals.</p><p align="justify">Last week, Ranbaxy had agreed to pay a fine of $500 million to settle litigation related to selling adulterated drugs in the US market. The company was charged with an intention to defraud, as well as failing to report the fact that its drugs did not meet required specifications.</p><p align="justify">Sujay Shetty, executive director at PricewaterhouseCoopers, said, &quot;US FDA, which is under pressure over quality concerns, will carry out additional scrutiny over ANDAs filed by Indian generic makers, and this would definitely slow the approval process....The shortage of staff at US FDA is already causing a delay in ANDA approvals.&quot;</p><p align="justify">Last year, Indian drug makers accounted for 178 of the 476 ANDA approvals by the US FDA. With 31 ANDA approvals, Aurobindo Pharma received the third-highest generic approvals, after Mylan Pharma and Apotex.</p><p align="justify">Tapan Ray, director general, Organisation of Pharmaceutical Producers of India, a representative entity of multinational pharmaceutical companies in India, said after recent incidents, including the Ranbaxy case, the image of India as a low-cost generic drugs manufacturer could be adversely impacted. &quot;In the backdrop of such high-decibel quality concerns raised by US FDA, the level of apprehension regarding the effectiveness of generic drugs made in India may increase, unless some tangible remedial measures are taken forthwith,&quot; he said.</p><p align="justify">In February, Jubilant Life Sciences had received a US FDA letter that cited major violations of manufacturing standards at its facility in Canada. The US FDA might delay drug approvals until Jubilant HollisterStier General Partnership took necessary corrective steps, Jubilant had said in a statement.</p><p align="justify">D G Shah, secretary general, Indian Pharmaceutical Alliance, believes competitors in the US generics market would use the recent episodes as tools to reduce demand for Indian generic versions in that market. &quot;There would be a collateral damage. Other large generic makers could create propaganda against Indian copycat drugs, through their connections with practitioners and other related parties,&quot; Shah said.</p><p align="justify">Not just Indian pharmaceutical companies, many others, too, had been issued cautionary letters by US FDA, either for violation of norms or for selling substandard drugs, Shah said. In March, Johnson &amp; Johnson had recalled about two million glucose meters, following the death of a patient in Europe after an inaccurate blood-sugar reading.</p><p align="justify">In 2007, US-based Merck &amp; Co had agreed to pay $4.85 billion to settle most claims its painkiller Vioxx had led to thousands of users reporting heart attacks and strokes. This was one of the costliest settlements in the pharmaceuticals sector.</p><p align="justify"><em>Reghu Balakrishnan in Mumbai</em></p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68011927877d7-trace').style.display = (document.getElementById('cakeErr68011927877d7-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr68011927877d7-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68011927877d7-code').style.display = (document.getElementById('cakeErr68011927877d7-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr68011927877d7-context').style.display = (document.getElementById('cakeErr68011927877d7-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr68011927877d7-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr68011927877d7-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 21102,
		&#039;title&#039; =&gt; &#039;Ranbaxy case may take a toll on other Indian drug makers&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last week, Ranbaxy had agreed to pay a fine of $500 million to settle litigation related to selling adulterated drugs in the US market. The company was charged with an intention to defraud, as well as failing to report the fact that its drugs did not meet required specifications.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sujay Shetty, executive director at PricewaterhouseCoopers, said, &amp;quot;US FDA, which is under pressure over quality concerns, will carry out additional scrutiny over ANDAs filed by Indian generic makers, and this would definitely slow the approval process....The shortage of staff at US FDA is already causing a delay in ANDA approvals.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, Indian drug makers accounted for 178 of the 476 ANDA approvals by the US FDA. With 31 ANDA approvals, Aurobindo Pharma received the third-highest generic approvals, after Mylan Pharma and Apotex.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Tapan Ray, director general, Organisation of Pharmaceutical Producers of India, a representative entity of multinational pharmaceutical companies in India, said after recent incidents, including the Ranbaxy case, the image of India as a low-cost generic drugs manufacturer could be adversely impacted. &amp;quot;In the backdrop of such high-decibel quality concerns raised by US FDA, the level of apprehension regarding the effectiveness of generic drugs made in India may increase, unless some tangible remedial measures are taken forthwith,&amp;quot; he said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In February, Jubilant Life Sciences had received a US FDA letter that cited major violations of manufacturing standards at its facility in Canada. The US FDA might delay drug approvals until Jubilant HollisterStier General Partnership took necessary corrective steps, Jubilant had said in a statement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
D G Shah, secretary general, Indian Pharmaceutical Alliance, believes competitors in the US generics market would use the recent episodes as tools to reduce demand for Indian generic versions in that market. &amp;quot;There would be a collateral damage. Other large generic makers could create propaganda against Indian copycat drugs, through their connections with practitioners and other related parties,&amp;quot; Shah said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Not just Indian pharmaceutical companies, many others, too, had been issued cautionary letters by US FDA, either for violation of norms or for selling substandard drugs, Shah said. In March, Johnson &amp;amp; Johnson had recalled about two million glucose meters, following the death of a patient in Europe after an inaccurate blood-sugar reading.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In 2007, US-based Merck &amp;amp; Co had agreed to pay $4.85 billion to settle most claims its painkiller Vioxx had led to thousands of users reporting heart attacks and strokes. This was one of the costliest settlements in the pharmaceuticals sector.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Reghu Balakrishnan in Mumbai&lt;/em&gt;
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;Rediff.com, 24 May, 2013, http://www.rediff.com/business/report/ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers/20130524.htm&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers-21247&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 21247,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 21102,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Ranbaxy case may take a toll on other Indian drug makers&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,generic drugs&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Business Standard



The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last week, Ranbaxy had agreed to pay a fine of $500 million to settle litigation related to selling adulterated drugs in the US market. The company was charged with an intention to defraud, as well as failing to report the fact that its drugs did not meet required specifications.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sujay Shetty, executive director at PricewaterhouseCoopers, said, &amp;quot;US FDA, which is under pressure over quality concerns, will carry out additional scrutiny over ANDAs filed by Indian generic makers, and this would definitely slow the approval process....The shortage of staff at US FDA is already causing a delay in ANDA approvals.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, Indian drug makers accounted for 178 of the 476 ANDA approvals by the US FDA. With 31 ANDA approvals, Aurobindo Pharma received the third-highest generic approvals, after Mylan Pharma and Apotex.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Tapan Ray, director general, Organisation of Pharmaceutical Producers of India, a representative entity of multinational pharmaceutical companies in India, said after recent incidents, including the Ranbaxy case, the image of India as a low-cost generic drugs manufacturer could be adversely impacted. &amp;quot;In the backdrop of such high-decibel quality concerns raised by US FDA, the level of apprehension regarding the effectiveness of generic drugs made in India may increase, unless some tangible remedial measures are taken forthwith,&amp;quot; he said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In February, Jubilant Life Sciences had received a US FDA letter that cited major violations of manufacturing standards at its facility in Canada. The US FDA might delay drug approvals until Jubilant HollisterStier General Partnership took necessary corrective steps, Jubilant had said in a statement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;D G Shah, secretary general, Indian Pharmaceutical Alliance, believes competitors in the US generics market would use the recent episodes as tools to reduce demand for Indian generic versions in that market. &amp;quot;There would be a collateral damage. Other large generic makers could create propaganda against Indian copycat drugs, through their connections with practitioners and other related parties,&amp;quot; Shah said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Not just Indian pharmaceutical companies, many others, too, had been issued cautionary letters by US FDA, either for violation of norms or for selling substandard drugs, Shah said. In March, Johnson &amp;amp; Johnson had recalled about two million glucose meters, following the death of a patient in Europe after an inaccurate blood-sugar reading.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In 2007, US-based Merck &amp;amp; Co had agreed to pay $4.85 billion to settle most claims its painkiller Vioxx had led to thousands of users reporting heart attacks and strokes. This was one of the costliest settlements in the pharmaceuticals sector.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Reghu Balakrishnan in Mumbai&lt;/em&gt;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 21102,
	&#039;title&#039; =&gt; &#039;Ranbaxy case may take a toll on other Indian drug makers&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last week, Ranbaxy had agreed to pay a fine of $500 million to settle litigation related to selling adulterated drugs in the US market. The company was charged with an intention to defraud, as well as failing to report the fact that its drugs did not meet required specifications.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sujay Shetty, executive director at PricewaterhouseCoopers, said, &amp;quot;US FDA, which is under pressure over quality concerns, will carry out additional scrutiny over ANDAs filed by Indian generic makers, and this would definitely slow the approval process....The shortage of staff at US FDA is already causing a delay in ANDA approvals.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, Indian drug makers accounted for 178 of the 476 ANDA approvals by the US FDA. With 31 ANDA approvals, Aurobindo Pharma received the third-highest generic approvals, after Mylan Pharma and Apotex.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Tapan Ray, director general, Organisation of Pharmaceutical Producers of India, a representative entity of multinational pharmaceutical companies in India, said after recent incidents, including the Ranbaxy case, the image of India as a low-cost generic drugs manufacturer could be adversely impacted. &amp;quot;In the backdrop of such high-decibel quality concerns raised by US FDA, the level of apprehension regarding the effectiveness of generic drugs made in India may increase, unless some tangible remedial measures are taken forthwith,&amp;quot; he said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In February, Jubilant Life Sciences had received a US FDA letter that cited major violations of manufacturing standards at its facility in Canada. The US FDA might delay drug approvals until Jubilant HollisterStier General Partnership took necessary corrective steps, Jubilant had said in a statement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
D G Shah, secretary general, Indian Pharmaceutical Alliance, believes competitors in the US generics market would use the recent episodes as tools to reduce demand for Indian generic versions in that market. &amp;quot;There would be a collateral damage. Other large generic makers could create propaganda against Indian copycat drugs, through their connections with practitioners and other related parties,&amp;quot; Shah said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Not just Indian pharmaceutical companies, many others, too, had been issued cautionary letters by US FDA, either for violation of norms or for selling substandard drugs, Shah said. In March, Johnson &amp;amp; Johnson had recalled about two million glucose meters, following the death of a patient in Europe after an inaccurate blood-sugar reading.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In 2007, US-based Merck &amp;amp; Co had agreed to pay $4.85 billion to settle most claims its painkiller Vioxx had led to thousands of users reporting heart attacks and strokes. This was one of the costliest settlements in the pharmaceuticals sector.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Reghu Balakrishnan in Mumbai&lt;/em&gt;
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;Rediff.com, 24 May, 2013, http://www.rediff.com/business/report/ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers/20130524.htm&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers-21247&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 21247,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 21102
$metaTitle = &#039;LATEST NEWS UPDATES | Ranbaxy case may take a toll on other Indian drug makers&#039;
$metaKeywords = &#039;medicines,generic drugs&#039;
$metaDesc = &#039;
-The Business Standard



The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last week, Ranbaxy had agreed to pay a fine of $500 million to settle litigation related to selling adulterated drugs in the US market. The company was charged with an intention to defraud, as well as failing to report the fact that its drugs did not meet required specifications.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sujay Shetty, executive director at PricewaterhouseCoopers, said, &amp;quot;US FDA, which is under pressure over quality concerns, will carry out additional scrutiny over ANDAs filed by Indian generic makers, and this would definitely slow the approval process....The shortage of staff at US FDA is already causing a delay in ANDA approvals.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, Indian drug makers accounted for 178 of the 476 ANDA approvals by the US FDA. With 31 ANDA approvals, Aurobindo Pharma received the third-highest generic approvals, after Mylan Pharma and Apotex.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Tapan Ray, director general, Organisation of Pharmaceutical Producers of India, a representative entity of multinational pharmaceutical companies in India, said after recent incidents, including the Ranbaxy case, the image of India as a low-cost generic drugs manufacturer could be adversely impacted. &amp;quot;In the backdrop of such high-decibel quality concerns raised by US FDA, the level of apprehension regarding the effectiveness of generic drugs made in India may increase, unless some tangible remedial measures are taken forthwith,&amp;quot; he said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In February, Jubilant Life Sciences had received a US FDA letter that cited major violations of manufacturing standards at its facility in Canada. The US FDA might delay drug approvals until Jubilant HollisterStier General Partnership took necessary corrective steps, Jubilant had said in a statement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;D G Shah, secretary general, Indian Pharmaceutical Alliance, believes competitors in the US generics market would use the recent episodes as tools to reduce demand for Indian generic versions in that market. &amp;quot;There would be a collateral damage. Other large generic makers could create propaganda against Indian copycat drugs, through their connections with practitioners and other related parties,&amp;quot; Shah said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Not just Indian pharmaceutical companies, many others, too, had been issued cautionary letters by US FDA, either for violation of norms or for selling substandard drugs, Shah said. In March, Johnson &amp;amp; Johnson had recalled about two million glucose meters, following the death of a patient in Europe after an inaccurate blood-sugar reading.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In 2007, US-based Merck &amp;amp; Co had agreed to pay $4.85 billion to settle most claims its painkiller Vioxx had led to thousands of users reporting heart attacks and strokes. This was one of the costliest settlements in the pharmaceuticals sector.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Reghu Balakrishnan in Mumbai&lt;/em&gt;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers-21247.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Ranbaxy case may take a toll on other Indian drug makers | Im4change.org</title>
    <meta name="description" content="
-The Business Standard



The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Ranbaxy case may take a toll on other Indian drug makers</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Business Standard</div><p align="justify"><br />The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals.</p><p align="justify">Last week, Ranbaxy had agreed to pay a fine of $500 million to settle litigation related to selling adulterated drugs in the US market. The company was charged with an intention to defraud, as well as failing to report the fact that its drugs did not meet required specifications.</p><p align="justify">Sujay Shetty, executive director at PricewaterhouseCoopers, said, &quot;US FDA, which is under pressure over quality concerns, will carry out additional scrutiny over ANDAs filed by Indian generic makers, and this would definitely slow the approval process....The shortage of staff at US FDA is already causing a delay in ANDA approvals.&quot;</p><p align="justify">Last year, Indian drug makers accounted for 178 of the 476 ANDA approvals by the US FDA. With 31 ANDA approvals, Aurobindo Pharma received the third-highest generic approvals, after Mylan Pharma and Apotex.</p><p align="justify">Tapan Ray, director general, Organisation of Pharmaceutical Producers of India, a representative entity of multinational pharmaceutical companies in India, said after recent incidents, including the Ranbaxy case, the image of India as a low-cost generic drugs manufacturer could be adversely impacted. &quot;In the backdrop of such high-decibel quality concerns raised by US FDA, the level of apprehension regarding the effectiveness of generic drugs made in India may increase, unless some tangible remedial measures are taken forthwith,&quot; he said.</p><p align="justify">In February, Jubilant Life Sciences had received a US FDA letter that cited major violations of manufacturing standards at its facility in Canada. The US FDA might delay drug approvals until Jubilant HollisterStier General Partnership took necessary corrective steps, Jubilant had said in a statement.</p><p align="justify">D G Shah, secretary general, Indian Pharmaceutical Alliance, believes competitors in the US generics market would use the recent episodes as tools to reduce demand for Indian generic versions in that market. &quot;There would be a collateral damage. Other large generic makers could create propaganda against Indian copycat drugs, through their connections with practitioners and other related parties,&quot; Shah said.</p><p align="justify">Not just Indian pharmaceutical companies, many others, too, had been issued cautionary letters by US FDA, either for violation of norms or for selling substandard drugs, Shah said. In March, Johnson &amp; Johnson had recalled about two million glucose meters, following the death of a patient in Europe after an inaccurate blood-sugar reading.</p><p align="justify">In 2007, US-based Merck &amp; Co had agreed to pay $4.85 billion to settle most claims its painkiller Vioxx had led to thousands of users reporting heart attacks and strokes. This was one of the costliest settlements in the pharmaceuticals sector.</p><p align="justify"><em>Reghu Balakrishnan in Mumbai</em></p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 21102,
		'title' => 'Ranbaxy case may take a toll on other Indian drug makers',
		'subheading' => '',
		'description' => '<div align="justify">
-The Business Standard
</div>
<p align="justify">
<br />
The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals.
</p>
<p align="justify">
Last week, Ranbaxy had agreed to pay a fine of $500 million to settle litigation related to selling adulterated drugs in the US market. The company was charged with an intention to defraud, as well as failing to report the fact that its drugs did not meet required specifications.
</p>
<p align="justify">
Sujay Shetty, executive director at PricewaterhouseCoopers, said, &quot;US FDA, which is under pressure over quality concerns, will carry out additional scrutiny over ANDAs filed by Indian generic makers, and this would definitely slow the approval process....The shortage of staff at US FDA is already causing a delay in ANDA approvals.&quot;
</p>
<p align="justify">
Last year, Indian drug makers accounted for 178 of the 476 ANDA approvals by the US FDA. With 31 ANDA approvals, Aurobindo Pharma received the third-highest generic approvals, after Mylan Pharma and Apotex.
</p>
<p align="justify">
Tapan Ray, director general, Organisation of Pharmaceutical Producers of India, a representative entity of multinational pharmaceutical companies in India, said after recent incidents, including the Ranbaxy case, the image of India as a low-cost generic drugs manufacturer could be adversely impacted. &quot;In the backdrop of such high-decibel quality concerns raised by US FDA, the level of apprehension regarding the effectiveness of generic drugs made in India may increase, unless some tangible remedial measures are taken forthwith,&quot; he said.
</p>
<p align="justify">
In February, Jubilant Life Sciences had received a US FDA letter that cited major violations of manufacturing standards at its facility in Canada. The US FDA might delay drug approvals until Jubilant HollisterStier General Partnership took necessary corrective steps, Jubilant had said in a statement.
</p>
<p align="justify">
D G Shah, secretary general, Indian Pharmaceutical Alliance, believes competitors in the US generics market would use the recent episodes as tools to reduce demand for Indian generic versions in that market. &quot;There would be a collateral damage. Other large generic makers could create propaganda against Indian copycat drugs, through their connections with practitioners and other related parties,&quot; Shah said.
</p>
<p align="justify">
Not just Indian pharmaceutical companies, many others, too, had been issued cautionary letters by US FDA, either for violation of norms or for selling substandard drugs, Shah said. In March, Johnson &amp; Johnson had recalled about two million glucose meters, following the death of a patient in Europe after an inaccurate blood-sugar reading.
</p>
<p align="justify">
In 2007, US-based Merck &amp; Co had agreed to pay $4.85 billion to settle most claims its painkiller Vioxx had led to thousands of users reporting heart attacks and strokes. This was one of the costliest settlements in the pharmaceuticals sector.
</p>
<p align="justify">
<em>Reghu Balakrishnan in Mumbai</em>
</p>',
		'credit_writer' => 'Rediff.com, 24 May, 2013, http://www.rediff.com/business/report/ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers/20130524.htm',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers-21247',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 21247,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 21102,
	'metaTitle' => 'LATEST NEWS UPDATES | Ranbaxy case may take a toll on other Indian drug makers',
	'metaKeywords' => 'medicines,generic drugs',
	'metaDesc' => '
-The Business Standard



The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that...',
	'disp' => '<div align="justify">-The Business Standard</div><p align="justify"><br />The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals.</p><p align="justify">Last week, Ranbaxy had agreed to pay a fine of $500 million to settle litigation related to selling adulterated drugs in the US market. The company was charged with an intention to defraud, as well as failing to report the fact that its drugs did not meet required specifications.</p><p align="justify">Sujay Shetty, executive director at PricewaterhouseCoopers, said, &quot;US FDA, which is under pressure over quality concerns, will carry out additional scrutiny over ANDAs filed by Indian generic makers, and this would definitely slow the approval process....The shortage of staff at US FDA is already causing a delay in ANDA approvals.&quot;</p><p align="justify">Last year, Indian drug makers accounted for 178 of the 476 ANDA approvals by the US FDA. With 31 ANDA approvals, Aurobindo Pharma received the third-highest generic approvals, after Mylan Pharma and Apotex.</p><p align="justify">Tapan Ray, director general, Organisation of Pharmaceutical Producers of India, a representative entity of multinational pharmaceutical companies in India, said after recent incidents, including the Ranbaxy case, the image of India as a low-cost generic drugs manufacturer could be adversely impacted. &quot;In the backdrop of such high-decibel quality concerns raised by US FDA, the level of apprehension regarding the effectiveness of generic drugs made in India may increase, unless some tangible remedial measures are taken forthwith,&quot; he said.</p><p align="justify">In February, Jubilant Life Sciences had received a US FDA letter that cited major violations of manufacturing standards at its facility in Canada. The US FDA might delay drug approvals until Jubilant HollisterStier General Partnership took necessary corrective steps, Jubilant had said in a statement.</p><p align="justify">D G Shah, secretary general, Indian Pharmaceutical Alliance, believes competitors in the US generics market would use the recent episodes as tools to reduce demand for Indian generic versions in that market. &quot;There would be a collateral damage. Other large generic makers could create propaganda against Indian copycat drugs, through their connections with practitioners and other related parties,&quot; Shah said.</p><p align="justify">Not just Indian pharmaceutical companies, many others, too, had been issued cautionary letters by US FDA, either for violation of norms or for selling substandard drugs, Shah said. In March, Johnson &amp; Johnson had recalled about two million glucose meters, following the death of a patient in Europe after an inaccurate blood-sugar reading.</p><p align="justify">In 2007, US-based Merck &amp; Co had agreed to pay $4.85 billion to settle most claims its painkiller Vioxx had led to thousands of users reporting heart attacks and strokes. This was one of the costliest settlements in the pharmaceuticals sector.</p><p align="justify"><em>Reghu Balakrishnan in Mumbai</em></p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 21102,
	'title' => 'Ranbaxy case may take a toll on other Indian drug makers',
	'subheading' => '',
	'description' => '<div align="justify">
-The Business Standard
</div>
<p align="justify">
<br />
The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals.
</p>
<p align="justify">
Last week, Ranbaxy had agreed to pay a fine of $500 million to settle litigation related to selling adulterated drugs in the US market. The company was charged with an intention to defraud, as well as failing to report the fact that its drugs did not meet required specifications.
</p>
<p align="justify">
Sujay Shetty, executive director at PricewaterhouseCoopers, said, &quot;US FDA, which is under pressure over quality concerns, will carry out additional scrutiny over ANDAs filed by Indian generic makers, and this would definitely slow the approval process....The shortage of staff at US FDA is already causing a delay in ANDA approvals.&quot;
</p>
<p align="justify">
Last year, Indian drug makers accounted for 178 of the 476 ANDA approvals by the US FDA. With 31 ANDA approvals, Aurobindo Pharma received the third-highest generic approvals, after Mylan Pharma and Apotex.
</p>
<p align="justify">
Tapan Ray, director general, Organisation of Pharmaceutical Producers of India, a representative entity of multinational pharmaceutical companies in India, said after recent incidents, including the Ranbaxy case, the image of India as a low-cost generic drugs manufacturer could be adversely impacted. &quot;In the backdrop of such high-decibel quality concerns raised by US FDA, the level of apprehension regarding the effectiveness of generic drugs made in India may increase, unless some tangible remedial measures are taken forthwith,&quot; he said.
</p>
<p align="justify">
In February, Jubilant Life Sciences had received a US FDA letter that cited major violations of manufacturing standards at its facility in Canada. The US FDA might delay drug approvals until Jubilant HollisterStier General Partnership took necessary corrective steps, Jubilant had said in a statement.
</p>
<p align="justify">
D G Shah, secretary general, Indian Pharmaceutical Alliance, believes competitors in the US generics market would use the recent episodes as tools to reduce demand for Indian generic versions in that market. &quot;There would be a collateral damage. Other large generic makers could create propaganda against Indian copycat drugs, through their connections with practitioners and other related parties,&quot; Shah said.
</p>
<p align="justify">
Not just Indian pharmaceutical companies, many others, too, had been issued cautionary letters by US FDA, either for violation of norms or for selling substandard drugs, Shah said. In March, Johnson &amp; Johnson had recalled about two million glucose meters, following the death of a patient in Europe after an inaccurate blood-sugar reading.
</p>
<p align="justify">
In 2007, US-based Merck &amp; Co had agreed to pay $4.85 billion to settle most claims its painkiller Vioxx had led to thousands of users reporting heart attacks and strokes. This was one of the costliest settlements in the pharmaceuticals sector.
</p>
<p align="justify">
<em>Reghu Balakrishnan in Mumbai</em>
</p>',
	'credit_writer' => 'Rediff.com, 24 May, 2013, http://www.rediff.com/business/report/ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers/20130524.htm',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'ranbaxy-case-may-take-a-toll-on-other-indian-drug-makers-21247',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 21247,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 21102
$metaTitle = 'LATEST NEWS UPDATES | Ranbaxy case may take a toll on other Indian drug makers'
$metaKeywords = 'medicines,generic drugs'
$metaDesc = '
-The Business Standard



The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that...'
$disp = '<div align="justify">-The Business Standard</div><p align="justify"><br />The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals.</p><p align="justify">Last week, Ranbaxy had agreed to pay a fine of $500 million to settle litigation related to selling adulterated drugs in the US market. The company was charged with an intention to defraud, as well as failing to report the fact that its drugs did not meet required specifications.</p><p align="justify">Sujay Shetty, executive director at PricewaterhouseCoopers, said, &quot;US FDA, which is under pressure over quality concerns, will carry out additional scrutiny over ANDAs filed by Indian generic makers, and this would definitely slow the approval process....The shortage of staff at US FDA is already causing a delay in ANDA approvals.&quot;</p><p align="justify">Last year, Indian drug makers accounted for 178 of the 476 ANDA approvals by the US FDA. With 31 ANDA approvals, Aurobindo Pharma received the third-highest generic approvals, after Mylan Pharma and Apotex.</p><p align="justify">Tapan Ray, director general, Organisation of Pharmaceutical Producers of India, a representative entity of multinational pharmaceutical companies in India, said after recent incidents, including the Ranbaxy case, the image of India as a low-cost generic drugs manufacturer could be adversely impacted. &quot;In the backdrop of such high-decibel quality concerns raised by US FDA, the level of apprehension regarding the effectiveness of generic drugs made in India may increase, unless some tangible remedial measures are taken forthwith,&quot; he said.</p><p align="justify">In February, Jubilant Life Sciences had received a US FDA letter that cited major violations of manufacturing standards at its facility in Canada. The US FDA might delay drug approvals until Jubilant HollisterStier General Partnership took necessary corrective steps, Jubilant had said in a statement.</p><p align="justify">D G Shah, secretary general, Indian Pharmaceutical Alliance, believes competitors in the US generics market would use the recent episodes as tools to reduce demand for Indian generic versions in that market. &quot;There would be a collateral damage. Other large generic makers could create propaganda against Indian copycat drugs, through their connections with practitioners and other related parties,&quot; Shah said.</p><p align="justify">Not just Indian pharmaceutical companies, many others, too, had been issued cautionary letters by US FDA, either for violation of norms or for selling substandard drugs, Shah said. In March, Johnson &amp; Johnson had recalled about two million glucose meters, following the death of a patient in Europe after an inaccurate blood-sugar reading.</p><p align="justify">In 2007, US-based Merck &amp; Co had agreed to pay $4.85 billion to settle most claims its painkiller Vioxx had led to thousands of users reporting heart attacks and strokes. This was one of the costliest settlements in the pharmaceuticals sector.</p><p align="justify"><em>Reghu Balakrishnan in Mumbai</em></p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Ranbaxy case may take a toll on other Indian drug makers

-The Business Standard The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals. Last week, Ranbaxy had agreed to pay a fine of $500 million to settle litigation related to selling adulterated drugs in the US market. The company was charged with an intention to defraud, as well as failing to report the fact that its drugs did not meet required specifications. Sujay Shetty, executive director at PricewaterhouseCoopers, said, "US FDA, which is under pressure over quality concerns, will carry out additional scrutiny over ANDAs filed by Indian generic makers, and this would definitely slow the approval process....The shortage of staff at US FDA is already causing a delay in ANDA approvals." Last year, Indian drug makers accounted for 178 of the 476 ANDA approvals by the US FDA. With 31 ANDA approvals, Aurobindo Pharma received the third-highest generic approvals, after Mylan Pharma and Apotex. Tapan Ray, director general, Organisation of Pharmaceutical Producers of India, a representative entity of multinational pharmaceutical companies in India, said after recent incidents, including the Ranbaxy case, the image of India as a low-cost generic drugs manufacturer could be adversely impacted. "In the backdrop of such high-decibel quality concerns raised by US FDA, the level of apprehension regarding the effectiveness of generic drugs made in India may increase, unless some tangible remedial measures are taken forthwith," he said. In February, Jubilant Life Sciences had received a US FDA letter that cited major violations of manufacturing standards at its facility in Canada. The US FDA might delay drug approvals until Jubilant HollisterStier General Partnership took necessary corrective steps, Jubilant had said in a statement. D G Shah, secretary general, Indian Pharmaceutical Alliance, believes competitors in the US generics market would use the recent episodes as tools to reduce demand for Indian generic versions in that market. "There would be a collateral damage. Other large generic makers could create propaganda against Indian copycat drugs, through their connections with practitioners and other related parties," Shah said. Not just Indian pharmaceutical companies, many others, too, had been issued cautionary letters by US FDA, either for violation of norms or for selling substandard drugs, Shah said. In March, Johnson & Johnson had recalled about two million glucose meters, following the death of a patient in Europe after an inaccurate blood-sugar reading. In 2007, US-based Merck & Co had agreed to pay $4.85 billion to settle most claims its painkiller Vioxx had led to thousands of users reporting heart attacks and strokes. This was one of the costliest settlements in the pharmaceuticals sector. Reghu Balakrishnan in Mumbai